15 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2031. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2031
Next term end
9
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2032 · High confidence
Also notable
Ends Oct 2031 · High confidence
Also notable
Ends Nov 2033 · High confidence
Also notable
Ends Oct 2031 · High confidence
Also notable
Ends May 2032 · High confidence
Also notable
Ends Jan 2032 · High confidence
Also notable
Ends May 2038 · High confidence
Also notable
Ends Mar 2042 · High confidence
Bio-Orthogonal Drug Activation
US 9,421,274
The most cited patent in this portfolio, cited by 59 later US patents, top 10% of utility patents granted in 2016 in our data. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Bio-Orthogonal Drug Activation
US 10,376,594
Cited by 10 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Chemically Cleavable Group
US 10,927,139
Cited by 8 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2033.
Pretargeting Kit, Method and Agents Used Therein
US 9,463,256
Cited by 47 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Pretargeting Kit for Imaging or Therapy Comprising a Trans-Cyclooctene Dienophile and a Diene
US 9,913,921
Cited by 15 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Agents for Clearing Biomolecules from Circulation
US 9,427,482
Cited by 17 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Cleavable Tetrazine Used in Bio-Orthogonal Drug Activation
US 11,617,799
Granted 2023. Computed term ends 2038.
Compounds Comprising a Linker for Increasing Transcyclooctene Stability
US 12,714,752
Granted 2026. Too new for citation comparison; protection runs to 2042.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 13, 2027The maintenance fee for Bio-Orthogonal Drug Activation (US 10,376,594) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Bio-Orthogonal Drug Activation (US 11,857,636) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 22, 2026
What they patent
The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Bio-Orthogonal Drug Activation (2013) | 4 in force | to May 2032 |
| Cleavable Tetrazine Used in Bio-Orthogonal Drug Activation | 2 in force | to May 2038 |
| Chemically Cleavable Group | 2 in force | to Oct 2034 |
| Bio-Orthogonal Drug Activation (2013) | 2 in force | to May 2032 |
| Compounds Comprising a Linker for Increasing Transcyclooctene Stability | 1 in force | to Mar 2042 |
| Compounds for Fast and Efficient Click Release | 1 in force | to Feb 2042 |
| Pretargeting Kit for Imaging or Therapy Comprising a Trans-Cyclooctene Dienophile and a Diene | 1 in force | to May 2032 |
| Agents for Clearing Biomolecules from Circulation | 1 in force | to Jan 2032 |
| Pretargeting Kit, Method and Agents Used Therein | 1 in force | to Oct 2031 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,463,256 | Pretargeting Kit, Method and Agents Used Therein In force · High confidence | In force | High confidence | |
| US 10,004,810 | Bio-Orthogonal Drug Activation In force · High confidence | In force | High confidence | |
| US 10,376,594 | Bio-Orthogonal Drug Activation In force · High confidence | In force | High confidence | |
| US 10,967,069 | Bio-Orthogonal Drug Activation In force · High confidence | In force | High confidence | |
| US 11,857,636 | Bio-Orthogonal Drug Activation In force · High confidence | In force | High confidence | |
| US 9,427,482 | Agents for Clearing Biomolecules from Circulation In force · High confidence | In force | High confidence | |
| US 9,913,921 | Pretargeting Kit for Imaging or Therapy Comprising a Trans-Cyclooctene Dienophile and a Diene In force · High confidence | In force | High confidence | |
| US 9,421,274 | Bio-Orthogonal Drug Activation In force · High confidence | In force | High confidence | |
| US 9,931,408 | Bio-Orthogonal Drug Activation In force · High confidence | In force | High confidence | |
| US 10,927,139 | Chemically Cleavable Group In force · High confidence | In force | High confidence |
Also on record, not counted in the 15: 10 applications pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.